Islet amyloid may have a pathological role in the development of Type 2 (non-insulin-dependent) diabetes mellitus. The prevalence of islet amyloid has been investigated on post-mortem pancreatic tissue from both diabetic and non-diabetic Pima Indian subjects who had previously been assessed by oral glucose tolerance tests. Islets were examined for amyloid deposits and for cellular immunoreactivity to pancreatic hormones and islet amyloid polypeptide, the constituent peptide of islet amyloid. Twenty of 26 diabetic subjects (77%) had islet amyloid, compared with one of 14 non-diabetic subjects (7%). Twelve of the diabetic subjects (46%) had amyloid in more than 10% of their islets, whereas only 4% of islets were affected in a single non-diabetic subject. Positive immunoreactivity for islet amyloid peptide was present in the islet amyloid and in islet cells in 54% of the diabetic and 50% of the non-diabetic subjects. Islet amyloid in diabetic Pima Indians may indicate a primary Beta-cell defect which interacts with insulin resistance to produce diabetes, or may develop as a result of Beta-cell dysfunction induced by insulin resistance and hyperglycaemia.
The observation by Opie in 1901 of hyaline infiltration, later shown to be amyloid, in islets of a diabetic patient was the first indication that islet pathology may be associated with diabetes [1] . Islet amyloid has been found in up to 87% of European Type 2 (non-insulin-dependent) diabetic subjects [2] [3] [4] and in diabetic patients in India [5] , Japan [6] and North America [7, 8] but its relationship to the pathophysiology of the disease is unknown. Islet amyloid may have a primary role in the aetiology of Type 2 diabetes in man [9, 10] : islet deposits precede the onset of glucose intolerance in spontaneously diabetic monkeys [11] and accumulation of amyloid adjacent to the Beta-cells may have a pathogenic effect on hormone secretion. Alternatively, amyloid formation may be a secondary phenomenon resulting from aberrant peptide processing or abnormal regulation of insulin secretion since amyloid formed from the same peptide is found in some insulinomas [12] .
The maj or protein constituent of pancreatic amyloid fibrils is a 37 amino acid peptide, islet amyloid polypeptide (IAPP) [13, 14] , (also known as diabetes associated peptide [9] , or "amylin" [15] . Islet amyloid is not found in Type 1 (insulin-dependent) diabetes nor in experimental models of diabetes in laboratory animals. However, cDNA analyses have shown species-specific variants of the peptide to be present in many animals including the mouse, dog and rat [16, 17] with amyloid being associated with diabetes only in the cat [18] , monkey [11] and man [2] [3] [4] [5] [6] [7] [8] .
Pima Indians, who live in Arizona, have a high prevalence of Type 2 diabetes [19] , are commonly obese and hyperinsulinaemic and exhibit a familial aggregation of insulin resistance [20] [21] [22] . Increased insulin resistance is thought to be the initial metabolic defect leading to diabetes in this group [23] [24] [25] [26] but pathological changes in the pancreas have not been reported. Clinical documentation of these subjects is extensive, including glucose tolerance tests and the presence of diabetes in relatives. They therefore form an ideal population to examine the relationship of amyloid formation to Type 2 diabetes. Quantitative estimates of islet amyloidosis and of intracellular immunoreactivity for IAPP have been determined in histological sections of available post-mortem pancreatic tissue from diabetic and non-diabetic individuals and the results related to the clinical history of the subjects.
Subjects and methods

Clinical dam
This study included 26 diabetic and 14 non-diabetic subjects on whom autopsy had been performed ( Table 1) . The clinical data were obtained from notes made on the last visit of the patients to the National Institute of Health Clinic and from hospital records and autopsy reports. Visits to the Clinic are a part of a longitudinal epidemio-body and (b) preabsorption of the diluted primary antibody with the appropriate antigen.
The total number of islet transections in the tissue specimen was counted on the slide stained for insulin. Quantitation of the islet sections containing amyloid was made on the adjacent histological section immunostained for IAPE Assessment of the histological sections was made by two independent observers (TN and AC) who were unaware of the subjects' clinical data. The slides were examined on a proj ected image, magnified x370. A complete tissue section was examined in adjacent fields and measurements made of the total area of tissue examined (range 12-200 mm 2, mean _+ 1 SD, 97 _+ 39 mm2), the total number of islets and the number of islets containing amyloid as shown by extracellular deposits staining pink with Congo red and immunoreactive for IAPR Fig.1 . Islet amyloid in an islet from a diabetic Pima Indian subject stained with immunoperoxidase for islet amyloid polypeptide. Amyloid deposits (large arrows) are present throughout the islet adjacent to the endocrine cells (small arrows). Scale bar = 10 gm logical study of diabetes among the Pima Indians in which every subject over the age of 5 years is examined approximately every two years. Each examination includes a medical history, a physical examination and an oral glucose tolerance test with 75 g glucose-equivalent carbohydrate load.
Glucose tolerance was categorised into normal, impaired or diabetic according to the World Health Organisation criteria [27] . Diabetes was determined in first-degree relatives (parents, siblings and offspring) who were examined in the research clinic by the same methods. Relatives who had not developed diabetes and were > 45 years old were considered flee of the disease whereas those who had not developed diabetes and were < 45 years old were considered to be indeterminate.
Immunohistochemistry and morphometry
A sample of pancreatic tissue from the body region of the pancreas was obtained at autopsy within 24 h of death. The tissues were fixed in 10% formaldehyde in 0.9% sodium chloride or in Bouin's solution and embedded in wax. Serial sections, 5 gin thick were cut from each tissue block and stained for islet peptides using the indirect immunoperoxidase method [28] and primary antibodies to insulin (diluted 1/1000), glucagon (diluted 1/2000; Dako Ltd, High Wycombe, UK) pancreatic polypeptide (diluted 1/1500; RIA, Washington, UK), somatostatin (diluted 1/2000; RIA, Washington, UK) and IAPP19-37 (diluted 1/1000). All sections were counterstained with haematoxylin. Two adjacent sections were stained for (a) IAPP or (b) insulin combined with Congo red to demonstrate islet amyloid. Only pancreatic specimens with good morphological preservation were studied and some specimens were omitted from both groups because of poor preservation. Specificity of the antibodies was demonstrated by lack of immunoreactivity following (a) omission of the primary anti-
Results
This study included 26 diabetic and 14 n o n -d i a b e t i c Pima Indians (12 with n o r m a l glucose t o l e r a n c e and two with i m p a i r e d glucose tolerance). T h e clinical and histological characteristics of each group are shown in Table 1 . Twenty of the 26 diabetic subjects (77%) had islet a m y l o i d identified by i m m u n o r e a c t i v i t y for I A P P and positive staining with Congo red (Fig. 1) . U p to 86% of the islets of diabetic subjects c o n t a i n e d a m y l o i d and in some cases a m y l o i d occupied most of the islet sections. Tables 2 and 3 show detailed clinical characteristics of the subjects. Twelve diabetic subjects (46%) had substantial a m y l o i d infiltration (deposits present in at least 10% of islet sections) whereas only 4% of islets were affected in only one nondiabetic individual. T h e r e was no correlation b e t w e e n the a Data collected at last biennial examination before death (0.5-13 years, median 2 years). b Subjects were not examined at the research clinic. IAPP = islet amyloid polypeptide, O = oral hypoglycaemic agent, I = insulin, N = no drug treatment had amyloid deposits and in 7 of 14 non-diabetic subjects (50%). Positive immunoreactivity for insulin, glucagon and somatostatin was present in all islets and for pancreatic polypeptide in some islets, of both diabetic and nondiabetic subjects. Ductular and exocrine fibrosis and deposition of fat were noted in the exocrine tissue in several subjects with no differences between the diabetic and non-diabetic groups. There was no evidence of lymphocytic infiltrates in islets of any of the 41 subjects.
Discussion
This is the first study to examine the prevalence of islet amyloid in post-mortem tissue from diabetic and nondiabetic subjects who had been characterised with a glucose tolerance test in life. In addition, Pima Indians represent a more homogeneous group than can be obtained from most routine hospital autopsies insofar as they appear to have exclusively Type 2 diabetes even when the disease presents at an early age [29, 30] . Islet amyloid was quence of IAPP predicted from cDNA analysis has an identical sequence to that of the peptide extracted from amyloid in diabetic subjects [34, 35] . Insulin and IAPP may be co-secreted from Beta cells [36] : rat-IAPP is released with insulin from isolated rat islets in response to glucose [37] . Hence, hypersecretion of insulin (and IAPP) in the course of diabetes could lead to amyloid formation. This may also be the mechanism of amyloid deposition in insulinomas which are characterised by excessive insulin and proinsulin production [12, 38] . High proinsulin levels have been detected in a patient with Type 2 diabetes who was known to have islet amyloid [39] . However, amyloid was not found in non-diabetic Pima Indians with large body mass index or impaired glucose tolerance which are clinical conditions associated with hyperinsulinaemia.
There could be several pathogenic mechanisms leading to Type 2 diabetes in Pima Indians, one of which is amyloid deposition; their glucose intolerance is characterised by insulin resistance whereas Beta cell dysfunction occurs later as diabetes develops [26] . Accumulation of amyloid between the islet cells and capillaries may directly affect Beta-cell function or disrupt the paracrine and neural control of endocrine secretion resulting in the disordered insulin production characteristic of Type2 diabetes [40, 41] . Alternatively islet amyloid could arise from abnormal function of the Beta cell induced by secondary hyperglycaemia, resulting in excessive formation and/or abnormal catabolism of the peptide.
found in 77% of the diabetic but in only 7% of the nondiabetic Pima Indians of comparable age, sex and weight. Thus, the prevalence of islet amyloid is high in Type 2 diabetes in Pima Indians and comparable to that in other ethnic groups [2, 3, 5, 8] . Early studies of the prevalence of islet amyloid in autopsy material from non-diabetic and diabetic subjects have suffered from inadequate separation of Type i and Type 2 diabetes and from lack of accurate identification of diabetes by glucose tolerance tests in life [5] [6] [7] . The absence of islet amyloid in the two subjects with glucose intolerance suggests that, unlike spontaneous diabetes in monkeys [9] , islet amyloid formation may not precede the onset of diabetes in man. However, it would require examination of more than one tissue specimen from the corpus region of the pancreas, where amyloid is found more commonly [2, 31] , to exclude the presence of amyloid in a subject [8] .
Immunoreactivity for IAPP has been found in secretory granules and lysosomes of Beta cells in nondiabetic subjects and in secretory granules of cats [32, 33] . A deficiency of IAPP in islet cells of diabetic subjects has been reported [4] . However, immunoreactivity for IAPP was detected in islet cells of diabetic and non-diabetic Pima Indians with similar frequencies. The inability to demonstrate immunoreactivity for IAPP in islet cells of some diabetic and non-diabetic subjects may result from imperfect tissue fixation and preservation: intracellular immunoreactive sites are more sensitive to autolysis than the extracellular amyloid deposits.
The mechanism of amyloid formation from lAPP is unknown. Formation of a genetically determined abnormal peptide in diabetes is unlikely since the amino acid se-
